United Therapeutics Corporation

BOVESPA:U2TH34 Stock Report

Market Cap: R$100.8b

United Therapeutics Management

Management criteria checks 2/4

United Therapeutics' CEO is Martine Rothblatt, appointed in Jan 1996, has a tenure of 28.92 years. total yearly compensation is $16.96M, comprised of 8.7% salary and 91.3% bonuses, including company stock and options. directly owns 1.49% of the company’s shares, worth R$1.51B. The average tenure of the management team and the board of directors is 15.7 years and 22.3 years respectively.

Key information

Martine Rothblatt

Chief executive officer

US$17.0m

Total compensation

CEO salary percentage8.7%
CEO tenure28.9yrs
CEO ownership1.5%
Management average tenure15.7yrs
Board average tenure22.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Martine Rothblatt's remuneration changed compared to United Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

US$1b

Jun 30 2024n/an/a

US$1b

Mar 31 2024n/an/a

US$1b

Dec 31 2023US$17mUS$1m

US$985m

Sep 30 2023n/an/a

US$900m

Jun 30 2023n/an/a

US$872m

Mar 31 2023n/an/a

US$728m

Dec 31 2022US$5mUS$1m

US$727m

Sep 30 2022n/an/a

US$707m

Jun 30 2022n/an/a

US$631m

Mar 31 2022n/an/a

US$687m

Dec 31 2021US$4mUS$1m

US$476m

Sep 30 2021n/an/a

US$462m

Jun 30 2021n/an/a

US$471m

Mar 31 2021n/an/a

US$405m

Dec 31 2020US$5mUS$1m

US$515m

Sep 30 2020n/an/a

US$469m

Jun 30 2020n/an/a

US$430m

Mar 31 2020n/an/a

US$528m

Dec 31 2019US$46mUS$1m

-US$104m

Sep 30 2019n/an/a

-US$92m

Jun 30 2019n/an/a

-US$118m

Mar 31 2019n/an/a

-US$150m

Dec 31 2018US$16mUS$1m

US$589m

Sep 30 2018n/an/a

US$543m

Jun 30 2018n/an/a

US$713m

Mar 31 2018n/an/a

US$484m

Dec 31 2017US$37mUS$1m

US$418m

Compensation vs Market: Martine's total compensation ($USD16.96M) is above average for companies of similar size in the BR market ($USD5.73M).

Compensation vs Earnings: Martine's compensation has increased by more than 20% in the past year.

CEO

Martine Rothblatt (69 yo)

28.9yrs

Tenure

US$16,958,057

Compensation

Dr. Martine A. Rothblatt, Ph D., J.D., M.B.A., founded United Therapeutics Corporation in 1996 and has been its Chief Executive Officer since June 26, 2016 and as its Chairman since 1996. Dr. Rothblatt ser...

Leadership Team

NamePositionTenureCompensationOwnership
Martine Rothblatt
Founder28.9yrsUS$16.96m1.49%
R$ 1.5b
Michael Benkowitz
President & COO8.5yrsUS$9.81m0.0058%
R$ 5.8m
James Edgemond
CFO & Treasurer11.9yrsUS$6.05m0.018%
R$ 18.2m
Paul Mahon
Executive VP28.9yrsUS$5.15m0.082%
R$ 82.9m
Dewey Steadman
Head of Investor Relationsno datano datano data
Holly Hobson
Associate Vice President of Human Resourcesno datano datano data
Kevin Gray
Senior Vice President of Strategic Operations & Logisticsno datano datano data
Patrick Poisson
Executive VP of Technical Operations15.7yrsno datano data
Leigh Peterson
Executive Vice President of Product Development & Xenotransplantationno datano datano data
Gil Golden
Senior VP & Chief Medical Officerno datano datano data

15.7yrs

Average Tenure

56yo

Average Age

Experienced Management: U2TH34's management team is seasoned and experienced (15.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Martine Rothblatt
Founder28.9yrsUS$16.96m1.49%
R$ 1.5b
Samuel Thier
Member of the Scientific Advisory Boardno datano datano data
Raymond Kurzweil
Independent Director22.9yrsUS$457.60k0.027%
R$ 27.3m
Louis Sullivan
Independent Director & Member of the Scientific Advisory Board22.3yrsUS$471.54k0.0072%
R$ 7.2m
Raymond Dwek
Independent Director & Member of the Scientific Advisory Board22.9yrsUS$456.54k0.0039%
R$ 4.0m
Christopher Patusky
Independent Vice Chairman & Lead Independent Director22.2yrsUS$532.60k0.0045%
R$ 4.5m
Christopher Causey
Independent Director21.4yrsUS$481.54k0.0082%
R$ 8.3m
Robert Bourge
Member of the Scientific Advisory Boardno datano datano data
Thomas Thompson
Independent Director22.9yrsUS$456.54k0.050%
R$ 50.7m
Magdi Yacoub
Member of the Scientific Advisory Boardno datano datano data
Judy Olian
Independent Director9.5yrsUS$488.66k0.013%
R$ 12.8m
Richard Giltner
Independent Director15.7yrsUS$513.66k0.039%
R$ 39.3m

22.3yrs

Average Tenure

76yo

Average Age

Experienced Board: U2TH34's board of directors are seasoned and experienced ( 22.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 09:00
End of Day Share Price 2024/12/18 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

United Therapeutics Corporation is covered by 37 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jasper HellwegArgus Research Company
James BirchenoughBarclays
Derek TallerBenchmark Company